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INTRODUCTION
Retinoblastoma is the most common intraocular malignancy of childhood [1] with 
an  incidence  of  approximately  1  in  14,000  to  34,000  live  births  per  year. 
Retinoblastoma accounts for 3% of all childhood malignancies in developed countries 
[2].  In developing countries such as India, retinoblastoma is usually the most frequent 
solid tumor seen in pediatric oncology units, suggesting that it might be more frequent 
in developing countries. In this setting, retinoblastoma is diagnosed late, usually when 
extraocular dissemination has occurred and the prognosis is poor. Late referral might 
account for the delayed diagnosis and treatment [3].
The survival rate of children with retinoblastoma has markedly improved over 
the  past  several  decades  in  developed  countries,  but  it  still  varies  in  developing 
countries. The 5-year survival rate is reported to be 95% and 87% respectively,  in 
Europe and the United States [4]. Few estimates of survival rates of retinoblastoma 
have been reported from the Asia region. In Malaysia and Taiwan the 5 year survival 
rates vary from 55-80.9% for unilateral cases and no patients with bilateral disease 
survive beyond 5 years [5]. However, data regarding five year survival rates in India is 
scant. In this background, this study was undertaken to evaluate the salient clinical 
and epidemiological features of retinoblastoma.
HISTORICAL ASPECTS
Retinoblastoma was described first by Peter Pawius from Amsterdam in 1597. 
In 1809, James Wardrop referred to the tumor as fungus hematodes. During the early 
years the disease was called by terms such as ‘soft cancer’. The precise origin of the 
tumor from the retina was a matter of dispute for several years. It was thought to arise 
from the inner nuclear layer, the nerve fibre layer, and the photoreceptors. Von Graefe 
called it a ‘retinal sarcoma’, Rudolf Virchow termed it ‘glioma of the retina’.  H. Knapp 
(1868) and Hirschberg (1868-9) introduced the term ‘glioma exophytum’ and ‘glioma 
endophytum’.  Flexner (1891) and Wintersteiner (1897) defined the natural history, 
histology of these tumors and their metastases. The term retinoblastoma was coined 
by Verhoeff (1922).  Von Graefe pointed out the need to remove a long section of the 
optic  nerve  at  the  time  of  enucleation  [6].    Reese  and  Ellsworth proposed  a 
classification of retinoblastoma in 1958 [7]. 
CLINICAL FORMS AND BIOLOGY
The unique place of retinoblastoma in oncology is due to its very distinct pattern 
of inheritance and from the fact that the RB1 gene was the first human cancer gene to 
be cloned. Retinoblastoma results from malignant transformation of primitive retinal 
cells  before final  differentiation.  Because these cells  disappear  within  the first  few 
years of life, the tumor is seldom seen after 3 years of age. The predisposing gene is 
at 13q14.
 Retinoblastoma may be heritable or non-heritable. About 60% of all patients 
with  retinoblastoma  have  a  nonheritable  form  of  the  disease  with  a  normal  life 
expectancy if they are cured of eye tumor.  The tumor is unilateral, the average age of 
diagnosis is about 24 months and the risk of other cancers is virtually indistinguishable 
from the normal population [8]. 85% of patients with unilateral retinoblastoma fall into 
this category.  In contrast, the remaining 40% have a heritable cancer predisposition 
syndrome due to RB1 germ line mutation. The average age at diagnosis is younger 
than the non-heritable form (newborn to 12 months) and they are predisposed to a 
variety of cancers throughout life. About 85% develop bilateral, multiple eye tumors. 
2-3% develop midline intracranial tumors that involve the pineal or suprasellar region 
and  are  referred  to  as  pinealoma,  primitive  neuroectodermal  tumor  and  trilateral 
retinoblastoma.
Hereditary retinoblastoma patients have an elevated risk of osteosarcomas, soft 
tissue  sarcomas  and  other  mesenchymal  tumors  through  their  teenage  years, 
melanomas and brain tumors through middle age and epithelial malignancies such as 
lung  and  bladder  cancer  into  later  life.  The  risk  of  second  malignancies  is  much 
greater in the field of radiation. This predisposition is due to the fact that hereditary 
patients carry germ line RB1 mutations (i.e. one allele of the tumor suppressor gene 
RB1 has mutated in all body cells), When a further mutogenic event affects the second 
allele  (“second  hit”),  the  cells  undergoes  malignant  transformation.  This  “two-hit 
theory”  was  first  proposed  by  Knudson  in  1971  [9],  thus  suggesting  that 
retinoblastoma gene functions in a recessive manner.  The deleted gene was later 
mapped to chromosome 13q14.1 to q 14.3 [10].  This retinoblastoma locus, RB1 is 
mutated in all  forms of  retinoblastoma, suggesting that chromosome 13 q14 is the 
gene locus for this tumor. Cavenee and co-workers using restriction fragment length 
polymorphic DNA probes compared DNA from normal and tumor tissue and found that 
one copy of  the region around RB gene was lost  during tumorigenesis.  This  was 
termed as loss of heterozygosity (or reduction of homozygosity). The authors showed 
that this genetic alteration was due to mitotic non disjunction or mitotic recombination, 
where a partial loss of one of a pair of chromosomes is repaired at mitosis by the 
duplication and transfer of a portion of its homolog [ 11].
‘THE FIRST HIT’: 
 The RB gene has 27 exons spanning over 200 kilobases of DNA. Less than 
10% of retinoblastoma patients have a constitutional chromosome 13 q abnormality 
(usually a deletion) [12]. Extensive deletions are associated with the 13 q syndrome, 
which also included growth and mental retardation, facial dysmorphism, microcephaly, 
skeletal  abnormalities  and  genitourinary  abnormalities.  Chromosomal  abnormalities 
are detected by karyotyping.
A majority of RB gene mutations are small alterations involving one or a few 
nucleotides.  These  can  be  detected  only  by  single  strand  conformational 
polymorphisms  [SSCP],  denaturing  gradient  gel  electrophoresis  [DGGE],  chemical 
cleavage  mismatch  detection  and  direct  sequencing.  The  majority  of  these  are 
frameshift  and  nonsense  mutations,  missense  mutations,  splicing  mutations  and 
mutations in noncoding regions that result in a truncated unstable protein product [13]. 
Germ line RB mutations can be detected by using truncated RB protein mutants.
Most of the new germline mutations are of paternal origin, suggesting that the 
gene responsible is more susceptible during spermatogenesis [14].
“ THE SECOND HIT”: 
Mutation of the second RB allele is due to chromosomal aberrations, usually 
recognized as loss of heterozygosity (LOH) by polymorphism analysis [12].   These 
mutations occur at a much higher rate than the first germ line mutation (103    vs. 107) 
[15]. Hence it is more sensitive to environmental factors such as ionizing radiation, 
thus  the  increased  risk  of  radiation  induced  malignant  tumors  in  survivors  of 
retinoblastoma.
The most common mechanism leading to LOH is mitotic recombination [50%], 
followed by non-disjunction with or without subsequent reduplication (~ 40%). After the 
second hit  has occurred, retinoblastoma cells rapidly accumulate additional genetic 
damage. It is possible than an additional mutation (third hit), probably involving a gene 
of the apoptotic pathway is necessary for final retinal tumor formation.
LOW PENETRANCE RETINOBLASTOMA:  
Penetrance:
 The frequency that a heritable disease is manifest in the offspring of affected 
individuals.
Expressivity:
 The variability of clinical manifestations in affected individuals.
Disease eye ratio:
 The ratio of the number of eyes containing tumors to the number of mutation 
carriers in a family. It identifies low penetrance retinoblastoma families by taking into 
account both penetrance and expressivity [16]. In general, reduced penetrance and 
expressivity tend to segregate in the same families [17]. The overall penetrance rate of 
retinoblastoma is 80-90%, which includes both high-penetrance and low-penetrance 
families [17]. Most low penetrance families have disease-eye ratios of 1:5 or greater. 
Most low-penetrance retinoblastoma results from mutations at the RB gene locus that 
result in an Rb protein with reduced activity [16,18,19]. One of the most common low 
penetrance mutations is a missense alteration at codon 661 [16,20].
ROLE OF RETINOBLASTOMA  PROTEIN:
The product of the RB1 gene is a 110-kd nuclear phosphoprotein that acts by 
binding and inhibiting several proteins with growth-stimulating activity pRB is a key 
substrate for G1 cyclin-cdk complexes, which phosphorylates target  gene products 
required for transition of the cell through G1.
The active pRb is the unphosphorylated gene product, which binds to several 
cellular proteins, among which is transcription factor E2F, which activates transcription 
of genes whose products are required for entry into the S phase of the cell  cycle. 
During progression through G1, pRB undergoes additional phosphorylation. The result 
is a hyperphosphorylated form that persists through the S1-G2 and M phases. pRB 
appears  to  function as  a  tumor  suppressor  at  least  in  part  by inhibiting cell  cycle 
progression past G1-S restriction point. Once cells traverse this restriction point and 
enters S phase, they become irreversibly committed to cell division.
Thus pRB stands as the major gatekeeper to control this critical point in growth 
regulation. Lack of pRB or its inactivation removes the pRB constraint on cell cycle 
control and the consequence is deregulated cell proliferation.  
OVERVIEW OF RETINOBLASTOMA
 Retinoblastoma is usually diagnosed between birth and the first 5 years of life. 
The tumor starts initially as one or more white masses usually in the posterior pole of 
the eye. Light reflected by the tumor causes a “cat’s eye” reflection in the pupil or a 
yellow glow rather a red glow as in the normal eyes. When the tumor destroys central 
vision, the presenting sign may be strabismus.
Initial tumors grow rapidly in the retina; as they expand they develop malignant 
characteristics leading to vitreous and subretinal seeding. The expanding mass leads 
to retinal detachment, neovascular glaucoma and/or intraocular hemorrhage before it 
spreads  beyond  the  eye.  Untreated,  most  intraocular  retinoblastomas  will  expand 
directly into the optic nerve, brain and orbit or spread via hematogenous dissemination 
to bone marrow, bone and other organs. Some tumors spontaneously involute leading 
to phthisis.
EPIDEMIOLOGY OF RETINOBLASTOMA
Retinoblastoma is  the  most  frequent  neoplasm of  the  eye  in  childhood and 
accounts for 3% of all pediatric cancers. The average incidence is one in 14-18,00 live 
cancers.  There is no sex or racial  predilection.  The human retina is not  terminally 
differentiated till 3 years of age. It is during this period, in which primitive photoreceptor 
cells are stimulated to differentiate into the mature retina , that cells are at high risk of 
sustaining oncogenic events that result in the development of a neoplasm. 
In developing regions of the world including Southern Asia, retinoblastoma is 
one of the single most common solid tumors of childhood; while in North America it is 
the sixth most  common solid  childhood tumor.  The varied incidence is  due to the 
varied incidence of unilateral non-heritable disease.
 The incidence of heritable retinoblastoma among the various populations of the 
world is remarkably constant, providing strong evidence that environmental influences 
play little role in the etiology of the hereditary form of this tumor [21]. 
In  marked  contrast  to  the  uniform  incidence  of  heritable  retinoblastoma 
worldwide,  there  are  striking  geographical  differences  in  the  indicence  of  non-
heritable, unilateral form of retinoblastoma. The increased incidence of non-heritable 
retinoblastoma in the tropical regions may possibly be due to a viral etiology [Human 
Papilloma Virus] [22],  though convincing evidence is not available.  Another theory 
proposed for the increased incidence of non-heritable retinoblastoma is that pregnant 
mothers in these countries eat a diet deficient in fruits and vegetables [22], leading to 
dietary  deficiencies  during  pregnancy.  Advanced  paternal  age  is  unequivocally 
associated  with  new  sporadic  germline  mutations  and  sporadic  heritable 
retinoblastoma [23].
PATHOGENESIS
Since all cells in a retinoblastoma tumor focus are identical, a new tumor cell will 
expand  symmetrically  as  a  round  or  hemispherical  lesion  that  is  homogenous. 
Because  tumor  growth  begins  in  a  single  retinoblast  cell,  all  intraocular 
retinoblastomas are initially confined to the retina.
Avascularity  severely  restricts  the  growth  potential  of  tumors.  Hence for  the 
tumor  to  expand  further,  tumor  angiogenesis  is  essential.  Angiogenesis  can  be 
demonstrated by measuring ‘relative tumor vascular density [RTVD]’. RTVD can be 
demonstrated  by  CD34  staining  for  vascular  endothelium  in  specially  stained 
histopathology sections. The RTVD is statistically greater in ocular tumors of patients 
with metastatic disease [24].
Another important property in tumor progress is loss of cellular adhesion or loss 
of  anchorage.  Retinoblastoma  cells  undergo  vitreous  or  subretinal  seeding  when 
mutations in the tumor suppressor gene PTEN allow them to grow without extracellular 
matrix anchorage dependence. Tumor cells that invade adjacent tissue spaces enter 
into different, low oxygen, low nutrient microenvironment. The final end result is large 
avascular vitreous and subretinal masses. Further tumor growth leads to total retinal 
destruction,  vitreous  or  subretinal  hemorrhage,  angle  closure  glaucoma  due  to 
pressure of the tumor pushing the iris lens diaphragm forward or from direct occlusion 
of  the chamber angle by tumor cells or  red blood cells or  anterior  chamber angle 
neovascularization.   Tumor  cells  may  invade  the  optic  nerve  and  grow  into  the 
chiasma and brain.   Less commonly,  they penetrate the sclera and expand as an 
orbital  mass lesion.  Since the  ability  to  metastasize requires  many mutations  that 
enable  the tumor  cell  to  penetrate  vessel  wall  layers,  survive in  the extravascular 
environment  and  develop  new  vessels  to  survive;   metastasis  implies  prolonged 
presence of viable tumor cells.
The function and structure of the eye ensure that retinoblastomas are diagnosed 
and treated before they metastasize.   Hence metastatic disease presents very rarely 
at initial diagnosis at least in developed countries.
CLASSIFICATION OF  INTRAOCULAR RETINOBLASTOMA  
The  Reese-Ellsworth  classification  published  originally   in  1964,  specifically 
predicts  the  likelihood  of  ocular  salvage  following  treatment  with  external  beam 
radiotherapy. The introduction of systemic chemotherapy in the 1980s led to the near 
abandonment of its use in most oncology centers. A new international classification 
system  based  on  the  natural  history  of  retinoblastoma  and  on   the  likelihood  of 
salvaging the eye when systemic chemotherapy is used as the primary treatment was 
developed.
REESE-ELLSWORTH CLASSIFICATION
This  is  a  group  classification  system  which  deals  only  with  organ-confined 
intraocular disease. In this system, eyes are divided into five groups on the basis of 
size, location and number of lesions and the presence of vitreous seeding [Table-1] 
[7 ]. 
Table   1 : Reese  –  Ellsworth  Grouping  of  Suitability  for  Management  of 
Retinoblastoma by Radiation Therapy.
STAGE DESCRIPTION
Group I. Very Favorable
I a Solitary tumor smaller than 4 dd at or behind the equator
I b Multiple tumors, none larger than 4 dd, all at or behind equator
Group II. Favorable
II a Solitary tumor 4-10 dd, at or behind equator
II b Multiple tumors 4-10 dd, at or behind equator
Group III. Doubtful
III a Any lesion anterior to the equator
III b Solitary tumor larger than 10 dd behind equator
Group IV. Unfavorable
IV a Multiple tumors, some larger than 10 dd
IV b Any lesion extending anteriorly to the ora serrata
Group V. Very unfavorable
V a Massive tumors involving more than half the retina
V b Vitreous seeding
Dd , disk diameter (1.5 mm)
THE INTERNATIONAL CLASSIFICATION SYSTEM
Table 2 : International classification of intraocular retinoblastoma [ 25 ]
Group A – Very low risk
• All tumors are 3 mm or smaller in greatest dimension, confined to the 
retina. 
• All tumors are located further than 3mm from the foveola and 1.5 
mm from the optic disc
Group B – Low risk
All remaining discrete retinal tumors without seeding
• All tumors confined to the retina not in group A
• Any tumor size and location with no vitreous or subretinal seeding
Group C- Moderate risk 
Discrete local disease with minimal focal subretinal or vitreous seeding
• Tumors must be discrete
• Subretinal fluid, present or past, without gross seeding, involving up 
to one quadrant of the retina
• Local subretinal seeding, present or past, less than 5 mm from the 
tumor
Focal fine vitreous seeding close to discrete tumor
Group D – High risk
Diffuse disease with significant vitreous and/or vitreous seeding
• Tumor(s) may be massive or diffuse
• Subretinal fluid, present or past, up to total retinal detachment
• Diffuse subretinal seeding, may include subretinal plaques or tumor 
nodules
• Diffuse or massive vitreous disease may include ‘greasy’ seeds or 
avascular tumor masses
Group E – Very high risk 
Presence of any one or more of these prognosis features
• Tumor touching the lens
• Neovascular glaucoma
• Tumor  anterior  to  anterior  vitreous  face  involving  ciliary  body  or 
anterior segment
• Diffuse infiltrating retinoblastoma
• Opaque media from hemorrhage
• Tumor necrosis with aseptic orbital cellulitis
• Phthisis bulbi
This is based on the natural history of retinoblastoma and on the likelihood of 
salvaging the eye when systemic chemotherapy is used as the primary treatment. 
The risk of loss of the eye due to the tumor is graduated form ‘very low’ for Group A to 
‘very high’ for Group E. In this system the morbidity of treatment increases from Group 
A to Group E.
ST. JUDE’S CLASSIFICATION
For patients undergoing enucleation, St. Jude Staging system is used which is a 
pathologic  staging  that  incorporates  other  features  known to  influence modality  of 
treatment and prognosis, such as choroidal involvement, optic nerve extension and 
presence of metastatic disease [26].
PATHOLOGY
 Retinoblastoma arises from the photoreceptor elements of the inner layer of the 
retina, usually extending into the vitreous cavity as a fleshy nodular mass (endophytic 
retinoblastoma).  Less  frequently,  it  extends  externally,  causing  secondary  retinal 
detachment;  in  this  case  there  is  no  localized  visible  vitreous  nodule  (exophytic 
retinoblastoma). 
         Macroscopically, retinoblastoma is soft and friable, and it tends to outgrow its 
blood supply, the result is necrosis and calcification. Because of friability of the tumor, 
dissemination within the vitreous and retina in the form of small white nodules (seeds) 
is common. In these cases, it may be difficult to differentiate multicentric primary tumor 
from disseminated tumor.
The  microscopic  appearance  depends  on  the  degree  of  differentiation. 
Undifferentiated retinoblastoma is  composed of  small,  round,  densely packed cells 
with hypochromatic nuclei and scant cytoplasm.
Homer Wright rosettes are composed of irregular circlets of tumor cells arranged 
around a tangle of fibrils with no lumen or internal limiting membrane. 
Flexner-Wintersteiner rosettes- a cluster of low columnar cells arranged around 
a central lumen bounded by an eosinophilic membrane are specific for retinoblastoma; 
seen in 70% of tumors. 
Fleurettes  are  less  common.  If  rosettes  are  present,  the  cells  exhibit  more 
ultrastructural  characteristics  of  photoreceptor  differentiation.  Especially  well-
differentiated tumors composed almost entirely of fleurettes have been called retinoma 
or retinocytoma.
CLINICAL FEATURES OF RETINOBLASTOMA
In a retrospective review of 1265 patients with retinoblastoma over a period of 
30 years – the most  comprehensive study of  retinoblastoma patients done so far, 
leucocoria was the presenting sign in 56.2% of the cases [28].Leucocoria is uniformly 
the most common presenting sign of retinoblastoma in most studies done in both the 
developing and the developed world [Table 3 ]. In a study done in Congolese children 
with retinoblastoma, 49% presented with Leucocoria [30]. In a study of 141 cases of 
retinoblastoma done in  Turkey,  retinoblastoma was  the  presenting sign in  82% of 
cases [31].  Tumors must occupy a large volume of  the globe before they produce 
leucocoria  that  is  visible  to  an  unaided  observer.  Leucocoria  correlates  with  the 
presence of advanced (RE group Va or Vb) disease. 
Table 3 : Presenting signs of retinoblastoma in various studies
New 
York
[ 28 ]
(n=900)
Finland
[32]
(n=136)
United 
Kingdom
[ 33]
(n=139)
Switzerland
[34]
(n=50)
Philadelphia
[35 ]
(n=87)
AIIMS
[29]
(n=392)
Leukocoria 56 54 32 62 55 72.2
Strabismus 20 18 20 20 21 10
Red eye 7 15 5 2 - -
Amblyopia 5 8 - 6 - -
Routine 
exam 3 1 9 2 4 1.5
Orbital 
cellulites 3 - - 2 - 0.5
Anisocoria 2 4 - 2 4 -
Hetero-
Chromia
1 1 - 2 2 -
Hyphema 1 - 1 - 1 0.25
‘Strange 
expression’ 0.5 - - - - -
Nystagmus 0.5 - - - - -
White iris 
nodule 0.5 - - - - -
Anorexia 0.5 - - - - -
Associated 
signs - - 7 - - -
Unspecified - - 26 - - Proptosis: 13
The likelihood of  observing leucocoria relates  directly  to the diameter  of  the 
pupil at the time of observation. Since the leucocoria is seen in dim light when the 
pupil  dilates  naturally,  parents  or  family  members  often  question  their  own 
observation. This will be reinforced if the pediatrician or primary care physician does 
not dilate the pupil and assures the family that there is no abnormality.  Strabismus is 
the second most common sign and usually correlates with macular involvement [28]. 
Hence strabismus in the first six months of life always requires an immediate retinal 
examination to rule out retinoblastoma. Small tumors in the foveola or near the foveola 
can  significantly  reduce  the  visual  acuity  in  that  eye.  Very  advanced  tumors  can 
become painful as a result of secondary glaucoma.
The various presenting features of retinoblastoma as seen in various studies 
have been summarized in Table 3.
FACTORS LEADING TO DELAY IN DIAGNOSIS OF RETINOBLASTOMA  : 
The American Academy of Pediatrics policy statement says that: 1] All infants 
should have a red reflex test by age two months in a darkened room. 2] For the test to 
be considered normal the examiner must see symmetrical reflections in the two pupils. 
3]  If  the examiner’s  efforts  to see the red reflex are not  successful,  the examiner 
should  either  dilate  the  pupil  before  performing  the  test  for  a  second  time  or 
immediately refer the child to an ophthalmologist [36].
A study done in the UK showed that nearly one quarter of patients were referred 
to an ophthalmologist only after 8 weeks of presentation. There was a significantly 
increased risk of diagnostic delay in younger patients, those presenting with squint 
rather  than  leucocoria,  and  those  first  presenting  to  a  health  visitor  rather  than  a 
general  practitioner.  The  risk  of  tumor  invasion  was  significantly  increased  by 
diagnostic delay. 
Hence  primary  health  care  professionals  require  education  about  the 
importance of ocular symptoms, especially squint, in pediatric patients [37].  Similarly, 
Erwenne  and  Franco reported  that  the  risk  of  extraocular  disease  was  strongly 
dependent  on  age  at  diagnosis  and  lateness  of  referral  [  3].  DerKinderen et  al 
reported that early diagnosis in bilateral retinoblastoma improved survival and visual 
outcome [38 ]. In developing countries presentation with advanced disease is common 
and outcome is often dismal [ 39]. In a study done in Buenos Aires late diagnosis was 
due to parental delays and failure of the pediatrician to recognize the condition [40].  In 
Argentina the survival rate for extraocular disease is only 36%, and all patients with 
central nervous system disease or distant metastases died [ 41].
PSEUDORETINOBLASTOMA: 
In 500 consecutive referrals for retinoblastoma, simulating lesions were found in 
212  of  the  500  patients  [42].  The  three  most  common  causes  were:   persistent 
hyperplastic vitreous (28%), Coat’s disease (16%0 and presumed ocular Toxocariasis 
(16%).  Other  conditions  that  simulate  retinoblastoma  include  congenital  cataract, 
retinopathy of prematurity and congenital retinal folds. Solid intraocular tumors appear 
hyperintense on T1 weighted MRI images and showed contrast  enhancement  and 
hypointense on T2 weighted images, whereas secondary serous or exudative retinal 
detachment  from  intraocular  lesions  showed  hyperintensity  on  both  T1  and  T2 
weighted images and no contrast enhancement [43].
EVALUATION
Anesthesia and a maximally dilated pupil and scleral indentation are required to 
examine the entire retina. Initial evaluation should include assessment of visual acuity 
and  an  indirect  ophthalmoscopic  examination  of  the  eyes.  Retinoblastoma usually 
appears  as  a  mass  projecting  into  the  vitreous,  although  the  presence  of  retinal 
detachment  or  vitreous  hemorrhage  can  make  visualization  difficult.  A  slit  lamp 
examination of anterior or posterior vitreous to look for vitreous seeding should be 
done. Tonometric measurement of intraocular pressure in all cases; measurement of 
corneal  diameter  and  an  ultrasonic  measurement  of  eye  length  are  helpful  in 
suspected glaucoma
IMAGING:
Additional imaging studies that aid in the diagnosis include B scan ultrasound, 
CT and MRI. B scan demonstrates intralesional calcium and helps in measuring tumor 
size. It can detect a tumor as small as 2 mm in diameter [44]. It is as good as CT in 
demonstrating presence of calcium in intraocular tumors. Ultrasound alone may lead 
to errors in diagnosis in cases of atypical retinoblastoma [no necrosis/calcification]. 
Hence CT scan is necessary in cases where calcium cannot be demonstrated by a B 
scan.   MRI of the brain and orbits (with gadolinium contrast and fat  suppression) 
helps  to  evaluate  extraocular  extension  and  optic  nerve  invasion  and  helps  to 
diagnose  ‘trilateral  retinoblastoma’.  Other  causes  of  leucocoria  can  also  be 
differentiated.  MRI  can  demonstrate  infiltrative  spread  to  the  Optic  Nerve, 
subarachnoid  seeding  and  involvement  of  the  brain.  Both  CT  and  MRI  help  in 
determining the extent of recurrent disease, extraocular spread and defining second 
primary tumor [45]. 
A  fluorescein  angiogram  is  useful  in  confirming  the  presence  of 
neovascularization of the iris in cases of retinoblastoma with glaucoma and/or chronic 
retinal  detachment.  It  also  helps  in  differentiating  active  lesions  (staining  and  dye 
accumulation) from inactive ones. It also helps in diagnosing a retinoma. Orbital films 
are of no value and should not be part of the workup. Fine needle aspiration should be 
done only in exceptional cases in which a diagnosis cannot be arrived at by any other 
means.  Specular  microscopy  of  the  corneal  endothelium  may  be  useful  in 
differentiating  retinoblastoma  cells  (dark  and  light  band  reflections)  from  keratic 
precipitates on corneal endothelial  surface (bright reflections with a peripheral dark 
rim) [46 ].
METASTATIC WORKUP: 
Metastatic  disease  occurs  in  approximately  10-15%  of  patients,  usually  in 
association  with  distinct  intraocular  features,  such  as  deep  choroidal  and  scleral 
invasion, or involvement of  the iris-ciliary body and optic nerve beyond the lamina 
cribrosa. Metastatic workup should be performed in these patients and whenever there 
is  clear  evidence  of  tumor  outside  the  eye.  Studies  should  include  bone  marrow 
aspiration and biopsy from multiple sites, a bone scan and lumbar puncture (to search 
for  tumor  cells  in  the  CSF).  These  studies  are  also  recommended  for  patients 
receiving chemotherapy or radiation therapy before enucleation, as proper histologic 
evaluation cannot be performed.
TREATMENT OF RETINOBLASTOMA
PRINCIPLES OF TREATMENT:
Management  of  retinoblastoma is aimed at  saving life  and preserving useful 
vision and thus it must be individualized. Factors to be considered in treatment include 
unilaterality or bilaterality of disease, potential for vision, and staging. 
SURGERY:
Enucleation is indicated for large tumors filling the vitreous for which there is 
little or no likelihood of restoring vision and in cases of tumor present in the anterior 
chamber or  in association with neovascular glaucoma. For optimal  staging, a long 
section (10-15mm) of Optic Nerve has to be removed with the globe.
FOCAL THERAPY:
Focal treatments are used for small tumors (<3-6mm), usually in patients with 
bilateral  disease,  and  in  combination  with  chemoreduction.  Photocoagulation  with 
argon laser is used to manage tumors situated at or posterior to the equator and to 
manage retinal neovascularization due to radiation therapy. Cryotherapy is used to 
manage  small  intraretinal  tumors  confined  to  the  sensory  retina  without  seeding 
[Shields JA].
An important  focal  method is  transpupillary  thermotherapy,  in  which focused 
heat  is  applied  at  sub  coagulation  levels.   Combination  of  thermotherapy  with 
chemotherapy has a synergistic effect. Hence thermo chemotherapy is becoming a 
very  important  component  in  the  management  of  intraocular  retinoblastoma.  In 
general, local control rates of 70-80% can be achieved.
RADIATION THERAPY:
Due to  increasing use of  chemoreduction in  conjunction with  intensive  focal 
therapy, external beam megavoltage radiation therapy usually is reserved for cases in 
which other  measures have failed,  usually because of  progression of  vitreous and 
subretinal seeding and for tumors adjacent to the optic nerve.  Because most patients 
undergoing radiation therapy have multifocal disease, the entire retinal surface has 
been irradiated to a uniform dose.  The recommended total  dose is 40-60 cGy in 
180-200 cGy fractions.  Many techniques can be used usually through lateral fields.
Three types of tumor regression have been categorized:
Type 1: Tumor shrinkage with calcium deposition; ‘cottage-cheese pattern’.
Type 2: Tumor is a grey homogenous mass characterized by partial shrinkage and 
loss of pink color of capillary injection. An annulus of atrophic pigment at the base of 
tumor is present.
Type 3: The mass has evidence of shrinkage, has lost pink color and has a nidus of 
calcium.  
Radiation  alone  can  cure  75-80%  of  patients.  Addition  of  cyrotherapy  or 
photocoagulation can improve results to 90%.
Radioactive plaque technique is used in the management of localized tumors. 
Indications include; solitary tumors with a diameter between 6-15 mm, tumor thickness 
of 10 mm or less and location of lesion greater than 3 mm from optic disc or fovea. I135 
is the most widely used. A control rate of 85-90% can be achieved.  
CHEMOTHERAPY:
Indications: 
 Extraocular disease,
 Intraocular disease with high risk histologic features,
 Bilateral disease [in conjunction with aggressive focal therapy].
Agents  include  platinum  compounds,  cyclophosphamide,  doxorubicin  and 
vincristine  .Chemotherapy  can  be  given  for  two  cycles  followed  by  specific  focal 
treatment after two months.
Adding local LASER hyperthermia to systemic carboplatin therapy enhances the 
binding of platinum to the DNA. 
UNILATERAL RETINOBLASTOMA:
Since  they  have  advanced  tumors  [RE  IV-V]  when  they  seek  treatment, 
enucleation is the treatment of choice being 80% curative.  Patients with high risk 
features on histology [deep choroidal invasion, involvement of anterior chamber, iris, 
ciliary body or retrolaminar optic nerve] need adjuvant therapy .Those with extraocular 
and  metastatic  disease  need  high  dose  chemotherapy,  hematopoietic  stem  cell 
rescue, radiation therapy to orbit and other areas of  bulky disease. 
BILATERAL RETINOBLASTOMA:
Since bilateral retinoblastoma is multiple, develop at an earlier age and patients 
are  at  risk  of  development  of  extraocular  tumors  throughout  life,  chemoreduction 
followed by aggressive focal therapy has replaced enucleation and EBT. The use of 
systemic  chemotherapy  for  cytoreduction,  coupled  with  intensive  sequential  focal 
therapy [cryotherapy, laser, photocoagulation, thermotherapy and brachytherapy] has 
resulted in increased eye salvage rates and a decrease in the use of radiation therapy. 
The best results are achieved with a combination of vincristine, carboplatin, etoposide. 
Salvage rates for RE I-III approaches 100% when these techniques are used.  For RE 
IV-V,  rates  are  not  better  than  50-70%  and  EBT  is  usually  needed.   Intraocular 
concentrations  are  7-10  times  higher  when  carboplatins  are  administered 
subconjunctivally.
PROGNOSIS: 
Factors  affecting  survival  include:  High  risk  histologic  features,  delay  in 
diagnosis and multiple episodes of recurrent disease in an eye.
 
Risk among offspring of survivors of retinoblastoma: The risk of retinoblastoma arising 
in  offspring  of  bilateral  [hereditary  disease]  is  45%.  The risk  is  2.5% in  cases  of 
offspring of unilateral retinoblastoma.
Risk among siblings: In the presence of family history, siblings of patients with bilateral 
tumors have a 45% risk while siblings of patients with unilateral tumors have a 30% 
risk. In absence of family history, siblings of patients with bilateral tumors have a 2% 
risk, while those with unilateral tumors have a 1% risk
AIMS AND OBJECTIVES
The aims of this study were to analyze;
• Age incidence
• Modes of presentation
• Time lag between onset of symptoms and presentation
• Staging
• Reasons for delay in presentation
• Correlation between delay in diagnosis and staging
• Radiological features
• Management and  follow-up of cases which were diagnosed as retinoblastoma.
MATERIALS AND METHODS
This  study  was  a  prospective  study  conducted  at  the  Regional  Institute  of 
Ophthalmology, Govt. Ophthalmic Hospital from May 2005 to September 2007. All the 
children suspected to have retinoblastoma and cases which were referred from other 
hospitals were subjected to detailed clinical examination. 26 consecutive patients [31 
eyes]  with retinoblastoma admitted from May 2005 to March 2008  were included in 
the  study.  Detailed  clinical  history  was  obtained  with  regard  to  the  nature  of  the 
disease like appearance of “amaurotic cats’ eye”, watering, pain, redness, protrusion 
of the eyeballs, squint, hyphaema, hypopyon, defective vision etc. The exact duration, 
progress and the eye or eyes involved was also noted.
In the family history details regarding the consanguinity between the parents 
and about the health and affection of the siblings and other relatives were noted. The 
family was also interviewed to determine if they had taken the child to a pediatrician or 
an ophthalmologist  after noticing the first  clinical  abnormality.  A record of the time 
between the onset of symptoms and diagnosis was made. Socioeconomic information 
was obtained from the family at diagnosis.
General examination included examination of other systems to rule out distant 
metastasis.  Ocular  examination  included  the  following:  vision,  pupillary  reaction, 
detailed fundus examination both direct and indirect under general anesthesia after 
total  mydriasis  with  atropinisation.  Ocular  tension  was  recorded  under  General 
Anesthesia  by  Perkin’s  hand-held  applanation  tonometer.   Investigation  included 
haematological examination pertaining to the disease and special investigations like 
CT scan orbit and brain, USG B scan, serum and aqueous LDH levels. In those cases 
where enucleation was done, the excised eye and the cut end of the optic nerve was 
subjected to histopathological examination. Those cases which needed radiotherapy 
was referred to Radiology Department, GH and chemotherapy to medical Oncology 
Department,  GH.  All  those  patients  were  asked  to  come  for  follow-up.  Careful 
examination of the empty socket and the apparently normal eye was done in the follow 
up at frequent intervals.
OBSERVATION AND DISCUSSION
In the present study a total number of 26 cases of established retinoblastoma 
were examined for the following:
Table 1: Age at presentation
Age at presentation No. of cases Percentage
< 1 yr 4 15.38
1 – 3 yr 14 53.84
> 3 yr 8 30.76
Table 2: Family History
Family history
No. of cases
< 1 yr 1-3 yr > 3 yr
Mean age at 
presentation
Present(5) 3 2 0 15.2 months
Absent(21) 1 12 8 34.14 months
Of the 26 cases examined, the age of onset of 53.8% cases was between 1-3 
years and the age of onset of 15.38% cases were below 1 year and 30.76% above 3 
years of age. The youngest child with RB in this study was 90 days old male with 
unilateral involvement. Majority of those patients with a family history of retinoblastoma 
presented with RB before the age of 1 year.  Our findings were similar to those of 
Abramson DH et al (96.5% patients presenting with a family history did so before the 
age of 24 months) [28]. Studies done in India show a similar age trend. A study done 
by Shanmugam MP et al shows the mean age at presentation of Retinoblastoma was 
23.98+/-23.37 months [48].
Table 3: Sex incidence
Sex No. of cases Percentage
Males 10 38.46
Females 16 61.84
In  our  study,  there  were  10(38.96%)  males  and  16(61.54%)  females.  Male: 
Female ratio was 0.62. Studies by Khandekar R (29 cases) [49], Mukhopadyaya S et 
al  [50] (study of 23 cases) showed that females were more affected similar to our 
study. However, other studies by Alegria V et al [51], Kaimbo et al [30] have shown 
that the gender ratio Male: Female > 1. 
Table 4: Laterality
Laterality No. of cases Percentage
Unilateral
Right eye
Left eye
11
10
42.30
38.46
Bilateral 5 19.23
Table 5 : Mean age at presentation according to laterality:
Laterality
No. of cases
< 1 yr 1-3 yr > 3 yr
Mean age at 
presentation
Bilateral 3 2 0 15.2 months
Unilateral 1 12 8 34.14 months
Retinoblastoma involved one eye in 21 cases, 80.7% cases and both eyes in 
5(19.23%) cases. For unilateral cases, the mean age at presentation was 2.58 years 
and for bilateral it was 15.2 months. Studies by Kaimbo et al and Watts showed that 
the unilateral cases presented at a mean age of 36 months and bilateral cases had a 
mean age at presentation of 12 months [30]. 
Table 6: Presenting sign
Presenting sign No. of cases Percentage
Leucocoria 22 70.96
Orbital cellulitis 3 9.67
Anterior Staphyloma 1 3.22
Hyphaema 1 3.22
Leucocoria with Strabismus 1 3.22
Nystagmus with Leucocoria 2 6.45
Leucocoria with proptosis 1 3.22
Leucocoria was the commonest presentation in our study accounting for 67.74% 
of cases.  Similar observations have been made in other studies done in New York, 
Philadelphia,  Finland,  Switzerland
[  32-35].  Leucocoria  was the most  common presenting sign in more than 50% of 
patients  with  retinoblastoma in  all  these  studies.  The  percentage  of  patients  who 
presented with orbital cellulitis was 9.67%; this high incidence has not been seen in 
other studies [ New York (3%), Switzerland (2%)]. This can be explained by the delay 
in diagnosis and referral  to an ophthalmologist by the primary care physicians and 
ignorance among the parents.
None  of  the  retinoblastoma  patients  in  our  study  were  detected  on  routine 
pediatric examination. Hence it is necessary that all infants should have a red reflex 
test  done  by  during  routine  visits  to  the  pediatrician  in  the  very  early  stage. 
Strabismus was a presenting sign in only 3.22% of our patients in contrast to other 
studies which report a higher incidence.  
Table 7: Intraocular Tension (by Perkin’s Tonometry)
Tension [mm Hg] No. of cases Percentage
10-20 3 11.11
20-30 10 37.03
30-40 10 37.03
40-50 4 14.81
About 88.89 % of patients had raised intraocular tension [> 20  mm Hg].  Raised 
intraocular  tension  is  a  major  differentiating  feature  of  retinoblastoma  from  other 
causes of Leucocoria. IOP was not recorded in 3 cases of orbital cellulitis and one 
case of anterior staphyloma.
Table 8: Calcification in ultrasound and CT
Calcification Ultrasound CT
Eyes % Eyes %
Present 27 87.09 31 100
Absent 4 12.90 0 0
Calcification was not detected by B scan Ultrasonography in 12.90% of cases. 
CT demonstrated calcification in all 31 eyes studied. Hence CT scan should be done 
in cases where calcium cannot be demonstrated by a B scan. [ 44 ].
Table 9: Staging (International Classification)
Stage No. of cases Percentage
A 0 0
B 0 0
C 11 35.48
D 11 35.48
E 9 29.03
Most  cases  presented  during  the  late  stages  of  disease,  hence  the  visual 
outcome in  almost  all  our  cases  was  poor.  Studies  in  developing  countries  have 
shown that  presentation  with  advanced disease is  common and outcome is  often 
dismal [ 39].  The reasons for presentation with advanced stage disease are delays in 
referral and parental delay in seeking treatment.
Table  10:  Time  interval  between  onset  of  symptoms  and  visit  to  an 
ophthalmologist 
First symptom Median lag time in weeks
Leukocoria 4 weeks(1 week – 52 weeks)
Orbital cellulitis 10 weeks (4 week – 1 4 weeks)
Others 2 weeks(1 week – 12 weeks)
Patients with orbital cellulitis had a greater time lag between onset of symptoms 
and referral to an ophthalmologist, while those with leukocoria had a lesser time lag. 
Since orbital cellulitis is a rare initial presenting sign of retinoblastoma there was a 
greater time lag between onset of disease and presentation to an ophthalmologist. 
The  overall  median  time  lag  was  5  weeks(  range  1-52  weeks)  for  all  types  of 
presenting signs. 
Table 11: Mode of treatment
Mode of treatment No. of cases Percentage
Enucleation 17 54.83
Enucleation followed by 
EBRT and chemo 3 9.67
EBRT + chemotherapy 9 29.03
Exenteration 1 3.22
Refused Treatment 1 3.22
Majority  of  our  patients  (64.5%)  underwent  enucleation.   Enucleation  was 
followed by EBRT and chemotherapy (9.67%) in cases which showed optic  nerve 
involvement on histopathological examination.
EBRT and Chemotherapy  (29.03%) was the mode of treatment for cases which 
had  demonstrable  intracranial  metastasis  and  bony  involvement.  One  eye  with 
Leucocoria and proptosis was found to have orbital  invasion and hence underwent 
exenteration.
In bilateral cases, the extensively diseased eye was enucleated and the less 
involved eye received EBRT and chemotherapy.
Table 12: Follow up of cases
Outcome No. of cases Percentage
Deaths 3 11.53
Recurrence in orbital socket 3 11.53
No recurrence (till study period) 13 50
Lost to follow-up 7 26.92
All  cases  were  followed  monthly  during  the  initial  six  months  following  their 
discharge  from  our  institution,  and  then  3  monthly  thereafter.  Three  cases  of 
retinoblastoma died during the study period due to systemic metastases. These 
patients  had  undergone  EBRT  and  chemotherapy  for  treatment  of  systemic 
disease.  Recurrence of tumor in the empty socket was seen in 3 cases which 
received further cycles of EBRT.  Recurrence of tumor was not demonstrated in 13 
cases during the study period. These cases had undergone enucleation alone and 
histopathology showed no optic nerve involvement. 7 cases were lost to follow-up. 
RESULTS AND CONCLUSION
A total of 26 retinoblastoma patients and 31 eyes were studied over a three year 
period for age at presentation, laterality, family history of retinoblastoma, presenting 
signs, time lag between symptom onset and presentation.  All the patients underwent 
detailed evaluation for disease staging. The treatment that  these patients had was 
recorded.
1. It was found that the mean age of presentation for patients with a positive family 
history was 15.2 months, while those with no family history of retinoblastoma 
presented at a later mean age of 34.14 months.
2. For  unilateral  cases  (21  cases  had  unilateral  disease),  the  mean  age  at 
presentation was 2.58 years while those with bilateral disease had a mean age 
at presentation of 15.2 months.
3. The  commonest  presenting  sign  was  leukocoria  (67.74%).  A  significant 
percentage of patients ( 9.67%) presented with orbital cellulitis.
4. Ultrasonography  demonstrated  intraocular  calcification  in  89.65% of  patients 
whereas  CT  scan  demonstrated  calcification  in  all  the  patients.  Hence  all 
patients with suspected retinoblastoma should undergo  a CT scan to detect 
calcification.
5. 68.4% of patients presented with high and very high risk disease [Stage D and 
E] as per International Classification System of staging, making vision salvage 
extremely difficult.
6. There was a overall median lag time of 5 weeks (range 1-52 weeks) between 
onset of symptoms and presentation to our center. The median lag time was 
greater (10 weeks) in those who presented with orbital cellulitis.
7. 64.5% the patients with retinoblastoma underwent enucleation.  About one-third 
underwent treatment for orbital extension and disseminated disease.
8. Our study shows that patients with retinoblastoma seek treatment in the later 
stages of  disease due to  delay  in  presentation  and delay in  referral.   Early 
referral  and timely presentation to  the ophthalmologist  is  necessary if  vision 
salvage is to be a reality.
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LIST OF SURGERIES
S. 
No NAME AG/SX IP NO DIAGNOSIS D. O. S PROCEDURE
1. GOPAL 65/M 382619 RE – IMC 10.07.05 RE-ECCE/PCIOL
2. PARVATHI 58/F 382759 BE–IMCL>R 17.07.05 RE-ECCE/PCIOL
3. KAMSALA 50/F 382947 BE–IMCL>R 31.07.05 LE-ECCE/PCIOL
4. SULOCHANA 60/F 390756 BE–IMCR>L 27.04.06 RE-ECCE/PCIOL
5. BABU 53/M 391787 BE-IMC R>L 10.05.06 RE-ECCE/PCIOL
6. KRISHNAVENI 70/F 393782 RE – MC 12.07.06 RE-ECCE/PCIOL
7. SAVITHRI 58/F 390999 BE–IMC R>L 18.08.06 RE-ECCE/PCIOL
8. SUSAI 59/M 396179 LE – IMC 03.10.06 LE-ECCE/PCIOL
9. ANANDAN 65/M 399979 RE – IMC 08.11.06 RE-ECCE/PCIOL
10. NARAYANAN 70/M 392147 LE – IMC 25.01.07 LE – SICS/PCIOL
11. VELUSAMY 52/M 392436 BE–IMC L>R 01.02.07 RE – SICS/PCIOL
12. MUNIAMMAL 65/F 399423 BE-IMC L>R 15.02.07 LE – SICS/PCIOL
13. RANI 52/F 399415 LE – MC 17.02.07 LE – SICS/PCIOL
14. ASHRAFUNISA 68/F 399442 BE-IMC R>L 22.02.07 RE – SICS/PCIOL
15. AYISHA BEE 55/F 399961 BE-IMC R>L 09.03.07 RE – SICS/PCIOL
16. SUNDARAMMA 65/F 400200 RE – MC 16.03.07 RE – SICS/PCIOL
17. SAMSHUDIN 58/M 400474 RE – IMC 23.03.07 RE – SICS/PCIOL
18. INDRANI 52/F 400576 RE – IMC 30.03.07 RE – SICS/PCIOL
19. MUNIAMMAL 60/F 394493
RE-FUNGAL 
CORNEAL ULCER 
WITH HYPOPYON
22.06.0
7
RE-TKP 9MM OVER 
8MM
20. RAVI 17/M 25789 LE CHALAZION 21.05.06 LE – I & C
21. KAVERI 37/F 27240 RE-PTERYGIUM 21.05.06 EXCISION
22. RAJAMMAL 35/F 384392
LE-FUNGAL 
CORNEAL ULCER 
WITH HYPOPYON
20.06.0
6
LE – AC WASH WITH 
AMP – B
23. MUNIAPPAN 59/M 83120 LE-PAN OPHTHALMITIS
26.11.0
6 LE-EVISCERATIONQ
24. SHANTHI 52/F 376292 RE-ABSOLUTE GLAUCOMA
08.12.0
6 RE-CYCLOCRYO
25. LAKSHMI 50/F 396830 RE-CHR. DACROCYSTITIS
07.02.0
7 RE DCT
26. BABU 09/M 396857 RE-TRAUMATIC ENDOPHTHALMITIS
07.02.0
7
RE-INTRA VITREAL 
INJ. OF 
BR.SP.ANTBIOTICS
27. MALAKONDIAH 55/M 387906 BE-SEC ACG RECOMBINED SUR
28. GIRIJA 45/F 402574 BE-PACG RE-AG SURGERY
29. SHANKAR 32/M 402574 RE-CHR. DACROCYSTITIS
08.05.0
7 RE – DCR
30. JAIBUNISA 15/F 397265 RE-OLD RHEG.RD 16.06.07
RE-RD SURG (360º 
ENCIRCLAGE WITH 
CRYO WITH SRF 
DRAINAGE)
